Lenalidomide (CC-5013; Revlimid) is structurally related to thalidomide but belongs to a new line of immunomodulatory drugs (IMiDs) with a more potent anti-angiogenic and antiinflammatory activity that is mediated by pleiotropic cytokine regulation. Among myeloid neoplasms, the most impressive treatment results with lenalidomide have been reported in del(5)(q31)-associated myelodysplastic syndrome (MDS) -45% complete cytogenetic response and an even higher rate of hematologic response. 1 Less impressive but notable hematologic response rates have also been documented in MDS without del(5q) 2 and primary (PMF) or post-polycythemia vera/ essential thrombocythemia (post-PV/ET MF) myelofibrosis. 3 Most recently, two single case studies reported lenalidomideinduced response in del(5q)-associated acute myeloid leukemia (AML). 4, 5 Herein we describe a similarly positive experience with lenalidomide therapy in three consecutive patients with del(5q)-associated PMF or post-PV MF (all three patients were JAK2V617F-positive); the report includes two new cases and follow-up information on a previously described patient. 3 Bone marrow histology in all instances was re-reviewed by two of the authors (AT and CAH) to confirm the diagnosis of PMF or post-PV MF as opposed to MDS with bone marrow fibrosis. Del(5)(q) was assessed by both conventional cytogenetics and fluorescent in situ hybridization (FISH) using probes for 5p15.2 (D5S23, D5S721) and 5q31 (EGR1). Quantitative allele-specific PCR was utilized for JAK2V617F mutation screening. 6 Clinical and laboratory parameters at baseline and post-lenalidomide treatment are presented in Table 1 .
Case 1 was a 75-year-old man with post-PV MF who was chemotherapy naïve before starting lenalidomide therapy (10 mg/day). At baseline, the patient displayed del(5)(q13q33) in all metaphases. After 3 months of side effect-free treatment with lenalidomide the complete blood count and peripheral blood smear normalized; hemoglobin improved from 9.4 to 14.2 g/dl, platelet count from 831 to 156 Â 10 9 /l, and leukoerythroblastosis was no longer present. Bone marrow biopsy disclosed complete resolution of hypercellularity, abnormal megakaryopoiesis, and myelofibrosis. Cytogenetic studies revealed 29 normal metaphases and one metaphase with del(5)(q); FISH for del(5)(q) was within normal limits. At 6 months, a complete cytogenetic remission was achieved both by karyotype and FISH; the percentage of abnormal nuclei by FISH decreased from 78 to 0%. At 9 months, JAK2V617F allele burden in bone marrow-derived DNA had decreased from the baseline of 4 to o1%. Although lenalidomide was discontinued after 6 months of therapy, because of protocol requirement, the patient remained in hematologic remission for an additional 12 months (that is a total of 15 months) before he relapsed with acute erythroid leukemia (AML M6); cytogenetic studies revealed eight abnormal metaphases with del(5)(q13q33) and other complex anomalies and JAK2V617F had reappeared. The patient did not respond to lenalidomide re-treatment.
Case 2 was a 69-year-old woman who presented with post-PV MF, and cytogenetic studies performed elsewhere were reported as showing monosomy 5, add(10)(q24), þ mar in 20 of 21 metaphases studied. The patient required treatment because of symptomatic marked splenomegaly and constitutional symptoms but did not tolerate either hydroxyurea (fever) or interferona. She was then started with lenalidomide therapy (10 mg/day), which she tolerated very well. At 9 months follow-up, the patient achieved complete hematologic remission with disappearance of leukoerythroblastosis, complete resolution of symptoms, no palpable splenomegaly, and partial bone marrow histological remission; cellularity decreased from 90 to 60% and reticulin fibrosis from grade 3 þ to 1-2 þ ). Cytogenetic studies revealed nine normal and 11 abnormal metaphases; del(5) (q13q33) and der(10)t(7;10)(q11.2;q11.2). Bone marrow FISH indicated that 33% of interphase nuclei had a 5p deletion that was verified by metaphase FISH while the EGR1 probe (5q31) was inserted into a chromosome 3 p-arm. Bone marrow JAK2V617F allele burden decreased from a baseline of 480 to 8%. At the time of this writing, more than 1 year from Table 1 Baseline and post-treatment clinical and laboratory features of three patients with del (5) Abbreviations: AA, all metaphases abnormal; AN, mixture of normal and abnormal metaphases; Hgb, hemoglobin; LDH, lactate dehydrogenase (normal level o250 U/L); post-PV MF, post-polycythemia vera myelofibrosis; PMF, primary myelofibrosis; Pt, patient; NN, all metaphases normal; WBC, white blood cell count; Tx, transfusion-dependent.
Letters to the Editor treatment initiation, the patient remains in hematological and clinical remission on 5 mg/day of lenalidomide (Table 1) . Case 3 is a 63-year-old man who presented with red blood cell transfusion-requiring PMF; del(5)(q13q33) was demonstrated in 17 of 20 bone marrow metaphases (85%), and del(5)(q) was also seen in 39.5% of 200 peripheral blood nuclei by interphase FISH (normal o6%). Patient was started with lenalidomide treatment (10 mg/day) after 3 months from initial diagnosis. After experiencing transient drug-induced myelosuppression and rash, he became red blood cell transfusionindependent after 2 months of lenalidomide treatment, and hemoglobin peaked at 15.5 g/dl at 6 months. At the 11-month follow-up evaluation, a complete hematological remission (including disappearance of leukoerythroblastosis) was documented (Table 1) , and repeat bone marrow biopsy revealed partial histological and cytogenetic remission: cellularity decreased from 80 to 50%, reticulin fibrosis from grade 3 þ to 1 þ , and the proportion of normal metaphases increased from 15 to 70%. Similarly, peripheral blood FISH percent nuclei for del(5)(q) decreased from a baseline of 39.5 to 7.5%. However, JAK2V617F allele burden in bone marrow-derived DNA did not change (Table 1) . At the time of this writing, the patient has been on lenalidomide therapy for 14 months and remains in complete hematological and clinical remission on 5 mg/day. The molecular and/or biological basis for lenalidomide activity against del(5q)-associated myeloid neoplasm is currently under investigation. Recent studies have demonstrated that lenalidomide promoted transcriptionally mediated upregulation of p21 WAFÀ1 (a cyclin-dependent kinase inhibitor that favors hypophosphorylation of the retinoblastoma protein and thus impairs G 1 -S transition), which appeared to have a differential effect on neoplastic cell lines versus normal myeloid progenitors: inhibition of growth in the former and enhanced proliferation in the latter. 7 Furthermore, the presence of del(5q) appeared to make tumor cell lines even more sensitive to lenalidomide effect; in the particular setting, lenalidomide induced G 0 /G 1 cell-cycle arrest and inhibition of both Gab1 (an adapter molecule) phosphorylation and PI3-kinase/Akt signaling. 8 Nevertheless, these observations do not adequately explain the remarkable association between lenalidomide activity and del(5q). Finally, based on our aforementioned limited experience, we encourage screening for del (5) The clinical course of polycythemia vera (PV) or essential thrombocythemia (ET) patients is frequently complicated by thrombohemorrhagic episodes, and the major goal of therapy is prevention and/or treatment of these complications. In early 2005, several groups virtually simultaneously reported the presence of a specific activating mutation (JAK2V617F) in the JH2 domain of JAK2 kinase in several myeloproliferative disorders (MPD); allelic frequency is estimated at above 90% for PV and 50% for both ET and primary myelofibrosis. 1 Although the role of JAK2V617F in the development of thrombosis in MPD patients remains to be precisely elucidated, early data in PV suggest an association between JAK2V617F allele burden determined at the time of diagnosis, and the risk of developing major thrombosis (AM Vannucchi et al., Blood 2006; 108: abstract 5). Similarly, some studies in ET have reported a higher rate of venous thromboses in JAK2V617F-positive patients as compared to those harboring wild-type JAK2.
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More recently, JAK2V617F has been detected in a significant proportion (31-59%) of patients presenting with splanchnic vein thrombosis. [3] [4] [5] In this setting, JAK2V617F represents a sensitive marker for 'latent' or 'occult' MPD (that is, MPD not identifiable
